PRESS RELEASE FROM EXTRAORDINARY GENERAL MEETING IN SCANDINAVIAN CLINICAL NUTRITION I SVERIGE AB (PUBL)

(NGM:SCN)

On Monday, May 12, 2008, the Extraordinary General Meeting in SCN decided to issue Units of shares and convertible bonds with preferential right for the company’s shareholders. The Board’s proposal to issue a greenshoe option was turned down. The main terms of the decisions can be found in the following.

Decision to issue convertible bonds and shares

The Extraordinary General Meeting (EGM) decided to issue shares and convertible bonds with preferential right for the company’s shareholders. The main terms of the share issue are as follows:

• Subscription right is due for those registered as shareholders on the record date, and for each one (1) held share, the shareholder will be given one (1) unit right. Each twelve (12) unit rights entitle to the subscription of one (1) Unit. One (1) Unit consists of one (1) share with a par value of SEK 0.10 at a subscription price of SEK 10 and one (1) convertible bond at par value of SEK 20. One (1) convertible bond gives the holder the right to convert it to one (1) new share in SCN at a price of SEK 20.

• The subscription price is SEK 30 per Unit.

• The record date is Monday, May 19, 2008.

• In the event that not all of the Units are subscribed for with preferential right, Units will primarily be allocated to those who have subscribed for Units with preferential right, pro rata in relation to their subscription with preferential right, and secondarily to those who have subscribed for Units without preferential right without being guarantors, pro rata in relation to the number of Units subscribed for. Remaining Units, if any, shall be allocated to those who have guaranteed the issue in relation to the guarantees pledged for. Subscription without preferential right can only take place in lots of 500 Units.

• The subscription period will be from May 28, 2008 – June 12, 2008.

80 per cent of the rights issue is secured through subscription engagements and underwriting guarantees from members of the board, major shareholders and other investors.

Decision regarding greenshoe option through a rights issue of shares

The EGM turned down the Board’s proposal regarding a greenshoe option.

For more information, please contact:

Ulf Söderberg, CEO, us@scnutrition.com, +46 708 13 22 81

Thomas Christensen, CFO, tc@scnutrition.com, +47 922 55 444

Scandinavian Clinical Nutrition AB (publ) works in R&D and sales of scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina and Ledactin. Core competence and strategic alliances within both R&D and sales, in combination with innovative and scientifically documented products, create the right conditions for profitable growth on the international market. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).